Nachrichten zu Arcutis Biotherapeutics

Startseite > Aktien > Arcutis Biotherapeutics > Nachrichten

Arcutis Biotherapeutics Aktie

Aktie

ISIN: US03969K1088 WKN: A2PYWE SYM: ARQT Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

10,020

USD

-1,52 %

-0,155 USD

Letzter Kurs 05.10.24 Nasdaq

Geldkurs

04.10.24

10,030

USD

600 STK

Briefkurs

04.10.24

10,040

USD

3.400 STK

Arcutis Biotherapeutics Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 04.10.24 · globenewswire · Arcutis Biotherapeutics
New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types 25.09.24 · globenewswire · Arcutis Biotherapeutics
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over 24.09.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology 19.09.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05.09.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 05.09.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 28.08.24 · globenewswire · Arcutis Biotherapeutics
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference 22.08.24 · globenewswire · Arcutis Biotherapeutics
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update 15.08.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update 14.08.24 · globenewswire · Arcutis Biotherapeutics
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 02.08.24 · globenewswire · Arcutis Biotherapeutics
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 01.08.24 · globenewswire · Arcutis Biotherapeutics

1
2
3
4
…
5

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 100 Leser

Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 ... 492 Leser
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE (roflumilast) Foam for the ... 132 Leser
New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic ... 104 Leser
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 100 Leser

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved ... 524 Leser
Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 ... 492 Leser
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update 492 Leser
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update 452 Leser
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update 396 Leser
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference 392 Leser
Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. 376 Leser
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results 360 Leser
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 340 Leser
Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment ... 316 Leser